SAN.PA Sanofi pre-market 27 Jan 2026: earnings ahead, amlitelimab momentum
SAN.PA stock opens pre-market on 27 Jan 2026 at €79.88 as investors position for Sanofi’s quarterly report due on 28 Jan 2026. The market will weigh revenue cadence, vaccine demand commentary and late‑stage data for amlitelimab. We summarise how pipeline news, valuation and dividends may move the share price and what to watch at the earnings call.
SAN.PA stock: earnings schedule and what matters
Sanofi (SAN.PA) reports earnings on 28 Jan 2026; that timing places the company in a busy European earnings week. Expect management to update full‑year guidance, U.S. and EU vaccine demand patterns, and near‑term revenue for Dupixent and its successors. One clear metric to watch is adjusted EPS versus consensus and commentary on U.S. vaccine volumes, which management flagged as soft in recent commentary.
Pipeline news driving SAN.PA stock sentiment
Recent phase 3 results for amlitelimab lift sentiment after Sanofi said the drug met primary and key secondary endpoints in atopic dermatitis. Positive trial news reduces clinical risk for a late‑stage asset that could offset Dupixent post‑patent pressures. Strategic moves, including possible bids in retinal therapeutics, also matter for medium‑term growth and were discussed in recent coverage source.
SAN.PA stock valuation and cash returns
Sanofi trades at PE 15.24 with EPS €5.24 and a dividend per share of €3.92, giving a yield near 4.91%. Market cap is about €96.77B and shares outstanding are 1,211,389,701. Key ratios: price/ book 1.33, price/ sales 2.11, and free cash flow yield about 12.44%. Those metrics point to defensive income appeal versus sector peers that trade at higher multiples.
SAN.PA stock technicals and trading snapshot
Price is €79.88, day range €79.46–€80.00, volume 1,425,193 which is below the 3‑month average of 1,822,192. Momentum indicators show neutral RSI at 48.39 and MACD histogram slightly positive. Bollinger middle band sits at €82.29, so short‑term pressure exists. Traders should watch support near the year low €76.15 and resistance at the 50‑day average €83.25.
Meyka AI rates SAN.PA with a score out of 100 and forecast
Meyka AI rates SAN.PA with a score out of 100: 73.76 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 and sector comparison, financial growth, key metrics, analyst consensus and forecasts.
Meyka AI’s forecast model projects a yearly price of €86.14 versus the current €79.88, implying an upside of 7.83%. The model also lists a monthly target €89.04. Forecasts are model‑based projections and not guarantees. For further data and company filings use our Sanofi page Meyka SAN page and recent market coverage source.
Analyst price targets, risks and sector context for SAN.PA stock
Analysts focus on Dupixent lifecycle, vaccine cycles and new asset readouts when setting targets. Upside catalysts: strong amlitelimab launch, successful retina acquisitions, and U.S. vaccine demand stabilization. Downside risks: weaker vaccine volumes than guided, generic pressure and regulatory setbacks. In the Healthcare sector, peers trade at higher PE multiples, so Sanofi offers a relative value plus dividend buffer.
Final Thoughts
Sanofi (SAN.PA) is a dividend‑oriented healthcare name trading at €79.88 ahead of its earnings report on 28 Jan 2026. The company combines a large market cap (€96.77B), steady EPS €5.24, and €3.92 per share in annual dividends. Recent amlitelimab phase 3 results reduce late‑stage pipeline risk and may support guidance clarity at the call. Meyka AI’s forecast model projects €86.14 for the year, an implied upside of 7.83% from today. Investors should weigh that projected upside against near‑term vaccine demand softness and execution risks. As an AI‑powered market analysis platform, Meyka flags Sanofi as a BUY grade (B+, 73.76/100) for income and selective growth exposure, but stresses forecasts are not guarantees and recommends monitoring the earnings release and management commentary closely.
FAQs
When does Sanofi report earnings and why does it matter for SAN.PA stock?
Sanofi reports on 28 Jan 2026. The release matters because management will update guidance, vaccine demand outlook and pipeline milestones that can move SAN.PA stock price and short‑term volatility.
What is Meyka AI’s price forecast for SAN.PA stock?
Meyka AI’s forecast model projects a yearly price of €86.14 versus the current €79.88, implying an upside of 7.83%. Forecasts are model projections and not guarantees.
What are key valuation metrics to watch for SAN.PA stock?
Watch PE at 15.24, EPS €5.24, price/ book 1.33, and free cash flow yield near 12.44%. Dividend per share is €3.92, giving a yield around 4.91% that supports total return assumptions.
What risks could pressure SAN.PA stock after earnings?
Main risks include weaker U.S. vaccine demand, lower Dupixent-related sales, clinical setbacks or regulatory delays, and any guidance cut. These would likely increase downside volatility for SAN.PA stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
